<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328259</url>
  </required_header>
  <id_info>
    <org_study_id>NAFLD in patient of IBD</org_study_id>
    <nct_id>NCT04328259</nct_id>
  </id_info>
  <brief_title>Prevalance of non_ Alcoholic Fatty Liver Diseases in Patient With Inflammatory Bowel Diseases Attending Assiut University Hospitals</brief_title>
  <official_title>Prevalance of non_ Alcoholic Fatty Liver Diseases in Patient With Inflammatory Bowel Diseases Attending Assiut University Hospitals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <brief_summary>
    <textblock>
      To assess the prevalance of non_alcoholic fatty liver diseases in inflammatory bowel disease
      patients and its relation to type of treatment given and disease severity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammatory bowel diseases (IBD) including Crohns disease (CD) and ulcerative colitis (UC)
      are chronic relapsing disorders that often require long-term therapy and follow up .

      They are recognized for their complex pathophysiology that involves innate immune system
      deregulation and altered microbiome in genetically predisposed individuals. Non-alcoholic
      fatty liver disease (NAFLD) includes a wide spectrum of disorders, ranging from hepatic
      steatosis (NAFL) to non-alcoholic steatohepatitis (NASH). NAFLD patients are at high risk for
      liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Also NAFLD is typically
      associated with altered metabolism and metabolic syndrome (MetS).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the prevalance of non-alcoholic fatty liver in inflammatory bowel disease participants</measure>
    <time_frame>one year</time_frame>
    <description>u/s will be done to all participants of inflammatory bowel disease to asses the rate of non-alcoholic fatty liver affection of all patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Correlation between immunosuppressive drugs and prevalance of non-alcoholic fatty liver affection in inflammatory bowel disease participants</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Inflammatory Bowel Disease Patients</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Inflammatory bowel disease patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Crohn's disease (CD) patients

          -  ulcerative colitis (UC) patients

        Exclusion Criteria:

          -  diabetic patients

          -  BMI equal and more than 30.0-34.9(class I obesity)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Shymaa A Ahmed, Resident</last_name>
    <phone>01065023156</phone>
    <email>Shymaaabdelhakam8989@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed A Ali, Assistant professor</last_name>
    <phone>+201027027525</phone>
    <email>Mabozeid2012@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017 Apr 29;389(10080):1741-1755. doi: 10.1016/S0140-6736(16)31711-1. Epub 2016 Dec 1. Review.</citation>
    <PMID>27914655</PMID>
  </reference>
  <reference>
    <citation>Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017 Apr 29;389(10080):1756-1770. doi: 10.1016/S0140-6736(16)32126-2. Epub 2016 Dec 1. Review.</citation>
    <PMID>27914657</PMID>
  </reference>
  <reference>
    <citation>de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):13-27. doi: 10.1038/nrgastro.2015.186. Epub 2015 Dec 2. Review.</citation>
    <PMID>26627550</PMID>
  </reference>
  <reference>
    <citation>European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7.</citation>
    <PMID>27062661</PMID>
  </reference>
  <reference>
    <citation>Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis. 2015 Oct;16(10):541-57. doi: 10.1111/1751-2980.12291. Review.</citation>
    <PMID>26406351</PMID>
  </reference>
  <reference>
    <citation>Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010 Jul;59(7):969-74. doi: 10.1136/gut.2009.205088.</citation>
    <PMID>20581244</PMID>
  </reference>
  <reference>
    <citation>Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016 May 20;17(5). pii: E774. doi: 10.3390/ijms17050774. Review.</citation>
    <PMID>27213358</PMID>
  </reference>
  <reference>
    <citation>McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015 May;62(5):1148-55. doi: 10.1016/j.jhep.2014.11.034. Epub 2014 Dec 1.</citation>
    <PMID>25477264</PMID>
  </reference>
  <reference>
    <citation>Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017 Jan;11(1):3-25. doi: 10.1093/ecco-jcc/jjw168. Epub 2016 Sep 22.</citation>
    <PMID>27660341</PMID>
  </reference>
  <reference>
    <citation>Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F; European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017 Jun 1;11(6):649-670. doi: 10.1093/ecco-jcc/jjx008.</citation>
    <PMID>28158501</PMID>
  </reference>
  <reference>
    <citation>Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976 Mar;70(3):439-44.</citation>
    <PMID>1248701</PMID>
  </reference>
  <reference>
    <citation>Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625-9.</citation>
    <PMID>3317057</PMID>
  </reference>
  <reference>
    <citation>Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006 Jun;55(6):749-53.</citation>
    <PMID>16698746</PMID>
  </reference>
  <reference>
    <citation>Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed). 1986 Jan 4;292(6512):13-5.</citation>
    <PMID>3080046</PMID>
  </reference>
  <reference>
    <citation>National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143-421.</citation>
    <PMID>12485966</PMID>
  </reference>
  <reference>
    <citation>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97.</citation>
    <PMID>11368702</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Al shymaa aAdel hakm Ahmed Ali</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Fatty Liver, Alcoholic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

